The ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. NGS-based AML MRD is being more widely adopted in drug development and studies aiming to improve ...
Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on developing precision medicines for ...
The ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. NGS-based AML MRD is being more widely adopted in drug development and studies aiming to improve ...
Expert Rev Hematol. 2012;5(4):395-407. AML: Acute myeloid leukemia; APL: Acute promyelocytic leukemia; CBF: Core-binding factor; CEBPA-DM: CCAAT enhancer-binding protein-α with double mutation ...
42 Our study shows that targets for minimal residual disease assessments should be personalized using next-generation sequencing because of AML being highly heterogeneous. For example, in this ...
Nana Kwame Wiredu Amoako is currently fighting for his life against Acute Myeloid Leukaemia (AML), a severe form of cancer.
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...
Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable ...
Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq â„¢ Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback